ClinicalTrials.gg
WithdrawnNCT06470035Updated Nov 18, 2026

Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Major Depressive Disorder (MDD)

An interventional study of Active VeNS Device and Sham VeNS Device in Major Depressive Disorder \(MDD and Depressive Disorder, Major, sponsored by Neurovalens Ltd.. Withdrawn at 2 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Neurovalens Ltd. · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
The study was withdrawn prior to initiation. No participants were enrolled.
Updated Nov 18, 2026Now WithdrawnStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 216 open to participants now, 258 under way, 26 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
1,285th of 1,323
0 · median 70
Started
2027
with 6 others
No phase
472 of 1,500
94 open now
Registered
1,330th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 1,285th largest by enrollment of the 1,323 interventional ones that give a count, is one of 7 that started in 2027, is one of 472 with no phase, and was the 1,330th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

216 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

211 more — sign in →

All 216 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

Trial title: A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of Major Depressive Disorder (MDD) - Modius Mood Study

The aim of this study: To better evaluate the efficacy of non-invasive electrical vestibular nerve stimulation (VeNS) as a method of treating major depressive disorder(MDD) , as compared to a sham control.

Allocation: Randomized to either active device or control device usage.

Endpoint classification: Efficacy Study Intervention Model: Parallel Assignment in 1:1 active to control allocation

03

Conditions studied

  • Major Depressive Disorder \(MDD
  • Depressive Disorder, Major

Keywords

  • VeNS
  • Depression
  • MDD
  • Vestibular stimulation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Adults, (US ≥ 22 years and ≤ 80 years, UK ≥ 18 years and ≤ 80 years) male or female at the time of signing informed consent
  3. Beck's Depression Inventory-ll (BDI-ll) score of ≥ 14 at Screening
  4. Established diagnosis of depression as confirmed at the time of screening by the Mini-International Neuropsychiatric Interview (MINI)
  5. A Generalized Anxiety Disorder (GAD-7) score \<10 at screening
  6. On anti-depressant medication to treat depression (participant must only be on one Selective Serotonin or Norepinephrine Reuptake Inhibitor (SSRI/SNRI) for at least 1 year prior to baseline visit, and no longer than 5 years)
  7. Stable dose of current prescribed antidepressant (SSRI/SNRI) medication to treat depression, 3 months prior to baseline appointment
  8. Maintain a stable prescribed medication and/or treatment regime to treat depression for the duration of the trial
  9. No change in regular medication for the duration of the trial (unless directed by a health care provider).
  10. Can speak / read English
  11. Ability and willingness to complete all study visits and procedures; in particular an agreement to engage with trying to use the device per the study protocol
  12. Ability and willingness to adhere to 30 minutes usage of the device daily for the duration of the trial
  13. Access to Wi-Fi for the duration of the study
  14. Access to a computer, laptop, iPad, tablet or smartphone (to complete study visits and complete online study questionnaires)
  15. Willingness to use a video calling platform to conduct remote study visits
  16. Agree not to undergo any extreme lifestyle changes during the duration of the study that could impact mood e.g. dietary , exercise changes
  17. Agree not to begin any complimentary or alternative therapies that may affect your mood during the time on the study e.g use of mental health apps, CBT

Exclusion criteria

Exclusion Criteria:

  1. Risk of persistent self-harm or suicide as confirmed by the Columbia Suicide Severity Rating Scale (CSSRS)
  2. Diagnosis or history of bipolar disorder
  3. History of or a current psychotic disorder such as schizophrenia or other non-mood disorder psychosis
  4. Diagnosis of substance use disorder within the past 12 months or current substance use dependence
  5. Use of recreational drugs (e.g nalgesics, depressants, stimulants, and hallucinogens). Subject can enrol after a of 30 days
  6. Female who is pregnant or breast-feeding
  7. History of diagnosed cognitive impairment / disorder such as delirium or dementia
  8. Previous or current diagnosis of a chronic viral infection, for example hepatitis or (potential damage to vestibular system, known as vestibular neuropathy).
  9. History of stroke or head injury requiring intensive care or neurosurgery (potential damage to neurological pathways affected by vestibular stimulation)
  10. Presence of permanently implanted batterypowered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator, etc.)
  11. History of epilepsy
  12. History of severe tinnitus or vertigo
  13. History of skin breakdown, eczema or other dermatological condition (e.g. psoriasis) affecting the skin behind the ears.
  14. History or presence of within the last year (except basal and squamous cell skin cancer and in-situ carcinomas)
  15. History of vestibular dysfunction or another inner ear disease
  16. Regular use (more than twice a month) of antihistamine medication within the last 6 months. The subject can opt to switch to Fexofenadine (non-drowsy) and may enrol after a wash-out period of 2 weeks
  17. Diagnosis of active migraines
  18. Previous use of Modius device or any VeNS device
  19. Participation in other clinical trials sponsored by Neurovalens
  20. Participation in any other depression studies at the time of enrolment and throughout this study duration
  21. Any other medical condition, or medication use, that in the opinion of the PI is likely to make the subject to VeNS.
  22. Failure to use device daily during trial participation (no more than 14 consecutive days usage drop without reasonable explanation)
  23. Persistent failure to comply with study protocol and procedures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Active VeNS

    The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.

    Device: Active VeNS Device

  • Sham comparator
    Sham VeNS

    The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.

    Device: Sham VeNS Device

Interventions

  • DeviceActive VeNS Device

    Battery powered non-invasive neurostimulation device

    Also known as: Modius Mood

  • DeviceSham VeNS Device

    Placebo comparator sham device (no active stimulation)

06

What researchers measure

Primary outcomes

  1. Hamilton Depression Rating Scale (HDRS-17)

    The HDRS (also known as the HAM-D) is the most widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS-17) pertaining to symptoms of depression experienced over the past week. Scoring is based on the 17-item scale and scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression; the maximum score being 52 on the 17-point scale. The HDRS-17 scoring shall be the Primary Outcome of the study and will be completed at baseline and each study visit.

    Time frame: Change in score from baseline to 6 weeks

  2. Hamilton Depression Rating Scale (HDRS-17)

    The HDRS (also known as the HAM-D) is the most widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS-17) pertaining to symptoms of depression experienced over the past week. Scoring is based on the 17-item scale and scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression; the maximum score being 52 on the 17-point scale. The HDRS-17 scoring shall be the Primary Outcome of the study and will be completed at baseline and each study visit. The proportion (%) of participants achieving the HDRS-17 minimal clinically important difference (≥3 point reduction) by the 6-week time point between the active and sham groups.

    Time frame: 6 weeks

Secondary outcomes

  1. WHO Disability Assessment Schedule 2.0 (WHODAS2)

    The WHO Disability Assessment Schedule 2.0 is a standardized assessment tool developed by the World Health Organization (WHO) to measure general health, disability levels and impairment across various domains of functioning, including mental and neurological disorders. It is designed to assess the impact of health conditions and disabilities on an individual's ability to participate in various life activities. The WHODAS 2.0 shall be a secondary outcome of this study, and will be completed at the baseline visit and repeated at each visit.

    Time frame: Change in score from baseline to 6 weeks

  2. Insomnia Severity Index (ISI)

    The Insomnia Severity Index (ISI) is a validated short, self-report screening assessment tool designed to evaluate insomnia by measuring an individual's perception of both day and night symptoms of insomnia. The Index consists of seven items which are each assessed in terms of perceived difficulty: falling sleep, staying asleep, and time of awakening, satisfaction with current sleep pattern, interference with daily functioning, noticeability by others of impact of lack of sleep, and degree of perceived distress or concern caused by the sleep problem. The ISI shall be a secondary outcome of the study and be completed at baseline and 6 weeks.

    Time frame: Change in score from baseline to 6 weeks

  3. Quality of Life (EQ-5D-5L)

    The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each level is rated on scale that describes the degree of problems in that area. The tool also has an overall health scale where the rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable. The EQ-5L-5D shall be completed at baseline and at 6 weeks. The EQ-5L-5D has previously been tested for reliability and validity.

    Time frame: Change in score from baseline to 6 weeks

  4. Hamilton Depression Rating Scale (HDRS-17)

    The HDRS (also known as the HAM-D) is the most widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS-17) pertaining to symptoms of depression experienced over the past week. Scoring is based on the 17-item scale and scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression; the maximum score being 52 on the 17-point scale.

    Time frame: Change in score at 4 week post-intervention timepoint

  5. WHO Disability Assessment Schedule 2.0 (WHODAS2)

    The WHO Disability Assessment Schedule 2.0 is a standardized assessment tool developed by the World Health Organization (WHO) to measure general health, disability levels and impairment across various domains of functioning, including mental and neurological disorders. It is designed to assess the impact of health conditions and disabilities on an individual's ability to participate in various life activities. The WHODAS 2.0 shall be a secondary outcome of this study, and will be completed at the baseline visit and repeated at each visit

    Time frame: Change in score at 4 week post-intervention timepoint

07

Study locations

2 sites
  • VA San Diego Healthcare System
    San Diego, California 92161, United States
  • Biomedical Science Research University of Ulster, Coleraine
    Belfast, Co.Antrim BT52 1SA, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Apr 2027, 3 months later.

Start moved once since we started tracking on Sep 25, 2026: Apr 2025 → Jan 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2024
First posted
Jun 24, 2024
StartEst.
Jan 6, 2027was Apr 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn The study was withdrawn prior to initiation. No participants were enrolled.
changed Nov 18, 2026
Start date
Apr 2025→Jan 6, 2027
Nov 18, 2026
Enrollment
170 (estimated)→0 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Withdrawn
    Why stopped The study was withdrawn prior to initiation. No participants were enrolled.
    Start date Apr 2025→Jan 6, 2027
    Enrollment 170 (estimated)→0 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06470035
Lead sponsor
Neurovalens Ltd.
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Jan 6, 2027 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Peter Colvonen
principal investigator · San Diego Healthcare System

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion